Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.
|Recent News||More >>|
Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at ENDO 2018
Ascendis Pharma A/S Announces Year-End 2017 Financial Results and Business Update Conference Call on March 28
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
|Upcoming Events||More >>|
|There are currently no events scheduled.|
|Primary IR Contact|
|Scott T. Smith|
Chief Financial Officer
Data provided by Nasdaq. Minimum 15 minutes delayed.